| Authors: |
Woodford R; Advanced Immunotherapy & Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; National Health and Medical Research Council Clinical Trials Unit, University of Sydney, Camperdown, NSW, Australia., Lorigan P; Melanoma Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Oudit D; Plastic Surgery Team, Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK., Abdulgawad A; Cellular Therapies & Early Phase Trials Team, Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK., Thistlethwaite F; Advanced Immunotherapy & Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Lim KHJ; Advanced Immunotherapy & Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. jon.lim@manchester.ac.uk.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. jon.lim@manchester.ac.uk. |
